Spectral Medical (TSE:EDT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Spectral Medical Inc. has announced a significant milestone in their Tigris trial, achieving a record-breaking enrollment of 116 patients as of June 2024. This surge includes the highest monthly enrollment to date, bringing the trial closer to its completion with only 34 more participants required. The company is advancing PMX, a potential septic shock treatment device, with the aim of obtaining U.S. FDA approval.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.